# Lexicon Pharmaceuticals, Inc. (LXRX)

> Source: Nexqual · https://nexqual.com/LXRX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Lexicon Pharmaceuticals, Inc. (LXRX), nexqual.com/LXRX" · informational, not investment advice.

**Price:** USD 1.48 (-0.34% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 1.49 · day 1.43–1.52 · 52w 1.1–2.68 · market cap $659M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $41.5M, net income -$61.1M (-147.4% margin) (SEC filings).
- Analysts: Buy (mean 2.17 on a 1–5 scale) (6 analysts), mean target USD 4.47 (range 1.69–8).
- Total return with dividends: 1Y +11.2% vs S&P 500 +14.8%; 5Y -72.0% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.05, revenue estimate $4.1M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: LXRX paid no cash dividend in the last five years.
- Short interest: 11.31% of float (as of 2026-10-15), 8.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $298K | $139K | $1.2M | $31.1M | $49.8M | $41.5M |
| Gross profit | $298K | $139K | $1.1M | $30.5M | $49.5M | — |
| Operating income | -$87.1M | -$101M | -$172M | -$197M | -$48.9M | -$54.5M |
| Net income | -$87.8M | -$102M | -$177M | -$200M | -$50.3M | -$61.1M |
| EPS (diluted) | -$0.60 | -$0.62 | -$0.80 | -$0.63 | -$0.14 | — |
| Free cash flow | -$88.2M | -$90.2M | -$162M | -$180M | -$67.9M | — |
| Gross margin | 100.0% | 100.0% | 92.9% | 98.0% | 99.4% | — |
| Operating margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% | -131.4% |
| Net margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% | -147.4% |
| Revenue growth | -98.8% | -53.4% | +766.2% | +2481.5% | +60.2% | — |
| Cash + short-term investments | $86.7M | $138M | $170M | $238M | $96.2M | — |
| Total debt | $0K | $48.6M | $99.5M | $100M | $54.0M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 15.9x · EV/Sales 12.5x · P/B 3.8x · Earnings yield -9.28% · Net cash $139M · EV $519M

## Analysts
Consensus Buy (mean 2.17 on a 1–5 scale), 6 analysts; mean target USD 4.47 (low 1.69, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-28 | Cantor Fitzgerald | Initiated | Overweight | $8 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +11.2% | -72.0% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +11.3% | -22.4% |
| Volatility (annualized) | 73.8% | 94.7% |
| Max drawdown | -46.2% (Jun 2026→Oct 2026) | -93.2% (Oct 2021→Mar 2025) |

## Dividends
LXRX paid no cash dividend in the last five years.

## Short interest
26,703,932 shares sold short, 11.31% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 28,793,507 shares (-7.3%). Days to cover: 8.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/LXRX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.05 | $-0.06 | +$0.01 | $4.1M | 3 |
| Next quarter (ends 2026-12-31) | $-0.04 | $-0.05 | +$0.01 | $11.2M | 3 |
| Current fiscal year (ends 2026-12-31) | $-0.17 | $-0.16 | −$0.01 | $37.2M | 3 |
| Next fiscal year (ends 2027-12-31) | $-0.19 | $-0.21 | +$0.02 | $16.9M | 4 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-05): ±22.0%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 103.0% | ±22.0% |
| 2027-01-15 | 78 | 151.2% | ±54.1% |
| 2027-04-16 | 169 | 109.4% | ±72.6% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.06 | −$0.05 | Miss −20.0% | — |
| — | Quarter ended Mar 31, 2026 | $0.00 | −$0.04 | Beat +$0.04 | — |
| — | Quarter ended Dec 31, 2025 | −$0.04 | −$0.07 | Beat +42.9% | — |
| — | Quarter ended Sep 30, 2025 | −$0.04 | −$0.07 | Beat +42.9% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).